We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Intercontinental Exchange
ICE
$87.2B
| $95.2M | 0.15% |
587,902
-16,229
| -3% | -$2.54M |
|
127
Automatic Data Processing
ADP
$109B
| $94.5M | 0.15% |
367,423
-15,320
| -4% | -$4.08M |
|
128
Crown Castle
CCI
$34.6B
| $93.6M | 0.14% |
1,052,667
+128,212
| +14% | +$11.8M |
|
129
McKesson
MCK
$104B
| $92.6M | 0.14% |
112,899
-178
| -0.2% | -$145K |
|
130
Public Service Enterprise Group
PEG
$38.7B
| $92.3M | 0.14% |
1,149,494
+30,181
| +3% | +$2.46M |
|
131
Public Storage
PSA
$61.5B
| $88.7M | 0.14% |
341,725
-4,455
| -1% | -$1.25M |
|
|
132
uniQure
QURE
$2.75B
| $88M | 0.14% |
3,678,640
+738,897
| +25% | +$28.5M |
|
133
Sherwin-Williams
SHW
$84.8B
| $87.4M | 0.14% |
269,649
-3,131
| -1% | -$1.05M |
|
134
Sempra
SRE
$58.1B
| $81.9M | 0.13% |
928,139
+381
| +0% | +$34.7K |
|
135
Starbucks
SBUX
$119B
| $80.8M | 0.13% |
959,195
-10,580
| -1% | -$892K |
|
136
CSX Corp
CSX
$94B
| $80.4M | 0.12% |
2,216,902
+26,997
| +1% | +$966K |
|
137
O'Reilly Automotive
ORLY
$75.1B
| $80.3M | 0.12% |
880,016
-9,205
| -1% | -$899K |
|
138
Moody's
MCO
$83.7B
| $79.8M | 0.12% |
156,218
+89
| +0.1% | +$43.4K |
|
139
Comcast
CMCSA
$87.3B
| $78.5M | 0.12% |
2,626,913
-80,829
| -3% | -$2.31M |
|
140
AstraZeneca
AZN
$269B
| $77.4M | 0.12% |
420,787
+20,678
| +5% | +$3.63M |
|
|
141
Mercado Libre
MELI
$94.5B
| $75.9M | 0.12% |
37,664
-40,964
| -52% | -$86M |
|
142
AerCap
AER
$23.4B
| $75.6M | 0.12% |
526,199
+2,374
| +0.5% | +$314K |
|
143
Mondelez International
MDLZ
$83.4B
| $75.5M | 0.12% |
1,401,839
+32,281
| +2% | +$1.86M |
|
144
GE Vernova
GEV
$240B
| $75M | 0.12% |
114,727
-5,032
| -4% | -$3.06M |
|
|
MRSH
145
Marsh
MRSH
$94.3B
| $74.8M | 0.12% |
403,265
-6,954
| -2% | -$1.3M |
|
146
Baker Hughes
BKR
$58.3B
| $74.1M | 0.11% |
1,627,663
-14,559
| -0.9% | -$690K |
|
147
Fastenal
FAST
$54.8B
| $73.8M | 0.11% |
1,839,595
-61,199
| -3% | -$2.58M |
|
148
Humana
HUM
$43.9B
| $72.7M | 0.11% |
283,778
+43,442
| +18% | +$11.4M |
|
149
Emerson Electric
EMR
$81.6B
| $71.8M | 0.11% |
541,130
-9,453
| -2% | -$1.25M |
|
|
BNY
150
Bank of New York Mellon
BNY
$103B
| $71.8M | 0.11% |
618,256
-27,935
| -4% | -$3.09M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.